Santhera
Santhera Pharmaceuticals AG is a Swiss biopharmaceutical company founded in 2004 through a merger between Germany-based Graffinity Pharmaceuticals AG and Swiss-based MyoContract AG. Santhera is focused on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases and has a fully integrated platform for the discovery and development of drug candidates. The company, headquartered in Switzerland, has operations in Liestal, Switzerland (near Basel) and in Heidelberg, Germany, as well as a business development office in Boston, MA, USA. Santhera's investors comprise Merlin Biosciences Limited, Oxford Bioscience Partners, NGN Capital, 3i Group plc, Carnegie Asset Management, The Novartis Venture Fund, Varuma AG, GIMV, Clariden Bank, The Dow Chemical Company, Heidelberg Innovation, TechnoStart, tbg, the Swiss Foundation for Research on Muscle Diseases, and private investors.

PrintPrint RateRate
Post Reply




Quick Reply
Your Name:
Your Comment:

smiling face wink grin cool nod sticking out tongue raised eyebrow confused shocked shaking head disapproval rolling eyes sad mad

Click a smilie to insert it into your message. You may use WSN Codes in your message.
Anti-Spam Image:
Type the letters and numbers shown on the left into the box on the right (this is to prevent automated submissions).
security image